Arizona Alzheimer's Disease Core Center
亚利桑那州阿尔茨海默病核心中心
基本信息
- 批准号:8118361
- 负责人:
- 金额:$ 5.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-15 至 2011-09-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This grant application requests five years of renewed support for the Arizona Alzheimer's Disease Core Center (ADCC). Scientifically, the ADCC is intended to optimize the development and use of its Cores, so as to capitalize on Arizona's scientific and organizational resources in the understanding, very early detection, and tracking of Alzheimer's disease (AD) and in the discovery of disease-slowing and prevention therapies. Organizationally, the ADCC is intended to establish a leading model of statewide collaboration in AD research.
The Administrative Core provides the leadership and support needed to optimize the development, interaction, and use of its Cores. Working closely with researchers inside and outside Arizona, the National Alzheimer's Coordinating Center (NACC), and other AD Centers, it promotes the development and progress of AD-related studies and collaborations. It administers a program for the statewide solicitation, competitive review, and support of pilot studies. It helps solve the challenges and fulfill the opportunities associated with the ADCCs statewide collaborative model, and ensures the ADCC's accountability to the NIA.
The Clinical Core maintains a large pool of clinically well characterized and annually assessed research subjects for the scientific study of AD and aging. The subjects include patients with AD and other dementias, patients with mild cognitive impairment (MCI), and normal controls, almost all of whom are enrolled in a brain donation program, and a growing pool of Latino and American Indian research subjects. This Core ensures the comparability and productive and appropriate use of subjects and data from its five clinical sites. It also promotes the productive and appropriate scientific use of longitudinally followed subjects, DNA, and data from three independently funded ancillary programs, yielding new information about the transition from cognitively normal aging to cognitive decline in persons at differential risk for AD.
The Data Management and Statistics Core maintains the ADCC's database, helps ensure the quality of data and the protection of subject confidentiality, and provides statistical services in a manner that best serves the needs of the statewide ADCC. It works closely with researchers, NACC, and other AD Centers, sharing data in the most productive, timely, and appropriate way.
The Neuropathology Core provides neuropathological diagnoses and extremely high-quality brain tissue from expired Clinical Core subjects to support research studies in Arizona and around the world. It also promotes the productive and appropriate use of biological materials from a large additional number of clinically and neuropathologically well characterized non-demented elderly subjects from its independently funded ancillary brain donation program, helping to address a critical need in the AD research community.
The Education and Information Core provides training, innovative educational and outreach programs, and strategic partnerships to promote the development of AD-related researchers, address needs of professional and family caregivers, provide information about the ADCC, and address unmet needs of Arizona's American Indian and rapidly growing Latino communities.
描述(由申请人提供):该赠款申请要求对亚利桑那州阿尔茨海默氏病核心中心(ADCC)的五年重新支持。从科学上讲,ADCC旨在优化其核心的发展和使用,以利用亚利桑那州的科学和组织资源来理解,非常早期的检测以及对阿尔茨海默氏病(AD)以及发现疾病缓慢和预防疗法的发现。在组织上,ADCC旨在建立一个全州范围的广告研究中的领先模型。
行政核心提供了优化核心发展,互动和使用所需的领导和支持。它与亚利桑那州内外的研究人员,国家阿尔茨海默氏症协调中心(NACC)和其他广告中心紧密合作,促进了与广告相关的研究和合作的发展和进步。它管理一项计划,用于全州招标,竞争性审查和对试点研究的支持。它有助于解决挑战并实现与ADCC全州协作模型相关的机会,并确保ADCC对NIA的问责制。
临床核心保持了大量的临床表征和每年评估的研究对象,以进行AD和衰老的科学研究。受试者包括AD和其他痴呆症患者,轻度认知障碍(MCI)的患者以及正常对照,几乎所有的人都参加了大脑捐赠计划,以及越来越多的拉丁裔和美洲印第安人研究对象。该核心确保了来自其五个临床部位的受试者和数据的可比性,生产性和适当使用。它还促进了从三个独立资助的辅助计划中纵向遵循的受试者,DNA和数据的生产性和适当的科学使用,从而产生了有关从认知正常衰老到认知能力下降的AD风险不同的人的认知能力下降的新信息。
数据管理和统计核心维护ADCC的数据库,有助于确保数据质量和对主题机密性的保护,并以最能满足全州ADCC需求的方式提供统计服务。它与研究人员,NACC和其他广告中心紧密合作,以最有生产力,及时和适当的方式共享数据。
神经病理学核心提供神经病理学诊断和从过期的临床核心受试者的极高脑组织,以支持亚利桑那州和世界各地的研究。它还从其独立资助的辅助大脑捐赠计划中促进了大量临床和神经病理学表征的未痴呆的老年受试者的生物材料的生产性和适当使用,从而有助于满足AD研究社区的关键需求。
教育和信息核心提供培训,创新的教育和推广计划以及战略合作伙伴关系,以促进与广告相关的研究人员的发展,满足专业和家庭护理人员的需求,提供有关ADCC的信息,并满足亚利桑那州美洲印第安人的未满足需求以及迅速发展的拉丁裔社区。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIC MICHAEL REIMAN其他文献
ERIC MICHAEL REIMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIC MICHAEL REIMAN', 18)}}的其他基金
Alzheimer's Prevention Initiative APOE4 Trial
阿尔茨海默病预防计划 APOE4 试验
- 批准号:
8605297 - 财政年份:2013
- 资助金额:
$ 5.65万 - 项目类别:
Cyclotron, PET and MRI Facility Improvement: A Scientific Resource for Arizona
回旋加速器、PET 和 MRI 设施改进:亚利桑那州的科学资源
- 批准号:
7898499 - 财政年份:2010
- 资助金额:
$ 5.65万 - 项目类别:
The GE PETtrace Cyclotron: A Scientific Resource for the State of Arizona
GE PETtrace 回旋加速器:亚利桑那州的科学资源
- 批准号:
7840169 - 财政年份:2010
- 资助金额:
$ 5.65万 - 项目类别:
PET, APOE & the Preclinical Course of Alzheimer's Disease
宠物、载脂蛋白
- 批准号:
8050044 - 财政年份:2008
- 资助金额:
$ 5.65万 - 项目类别:
PET, APOE & the Preclinical Course of Alzheimer's Disease
宠物、载脂蛋白
- 批准号:
7596924 - 财政年份:2008
- 资助金额:
$ 5.65万 - 项目类别:
PET, APOE & the Preclinical Course of Alzheimer's Disease
宠物、载脂蛋白
- 批准号:
7383433 - 财政年份:2008
- 资助金额:
$ 5.65万 - 项目类别:
PET, APOE & the Preclinical Course of Alzheimer's Disease
宠物、载脂蛋白
- 批准号:
8234924 - 财政年份:2008
- 资助金额:
$ 5.65万 - 项目类别:
相似国自然基金
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
- 批准号:82372073
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
藤黄科植物中多靶点抗痴呆症天然先导化合物及其作用机制研究
- 批准号:31770379
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
BDNF前肽片段调控Alzheimer疾病模型海马gamma振荡的突触环路机制研究
- 批准号:81701070
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
神经元轴突起始节异常在老年性痴呆症的发生发展中的作用
- 批准号:31630028
- 批准年份:2016
- 资助金额:267.0 万元
- 项目类别:重点项目
阿尔茨海默病神经免疫系统异常的机制研究
- 批准号:31530089
- 批准年份:2015
- 资助金额:285.0 万元
- 项目类别:重点项目
相似海外基金
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 5.65万 - 项目类别:
Joint Estimate Diffusion Imaging (JEDI) for improved Tissue Characterization and Neural Connectivity in Aging and Alzheimer's Disease
联合估计扩散成像 (JEDI) 可改善衰老和阿尔茨海默病的组织表征和神经连接
- 批准号:
10662911 - 财政年份:2023
- 资助金额:
$ 5.65万 - 项目类别:
GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular
缓释 PNA5 的 GMP 生产和 IND 启用研究:一种治疗阿尔茨海默氏病相关痴呆和血管性认知障碍患者认知障碍的新疗法
- 批准号:
10819329 - 财政年份:2023
- 资助金额:
$ 5.65万 - 项目类别:
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 5.65万 - 项目类别: